



September 15, 2022

OFFICERS

Susan Dentzer, Chair
The Hon. Michael N. Castle, Chair Emeritus
The Hon. Bart Gordon, Vice Chair
Mary Woolley, President
E. Albert Reece, MD, PhD, MBA, Secretary
Amy Comstock Rick, JD, Treasurer

BOARD MEMBERS

Tenley E. Albright, MD
Georges C. Benjamin, MD
Nancy Brown
The Hon. Charlie Dent
Mikael Dolsten, MD, PhD
Victor J. Dzau, MD
Kafui Dzirasa, MD, PhD
Arthur C. Evans Jr., PhD
Dario Gil, PhD
William N. Hait, MD, PhD
Mary J.C. Hendrix, PhD
The Hon. Rush D. Holt, PhD
James L. Madara, MD
Mark McClellan, MD, PhD
Michelle McMurry-Heath, MD, PhD
Jessica L. Mega, MD, MPH
Herbert Pardes, MD
Sudip S. Parikh, PhD
Harold L. Paz, MD, MS
Guillermo Prado, PhD
Derek Rapp
Laing Rogers
Lewis G. Sandy, MD, FACP
The Hon. Donna Shalala
Larry J. Shapiro, MD
Deborah Trautman, PhD, RN, FAAN
M. Roy Wilson, MD
Cynthia Zagieboylo

The Honorable Joseph Biden
The White House
1600 Pennsylvania Avenue, NW
Washington, DC

The Honorable Nancy Pelosi
Speaker of the House
United States Capitol
Washington, DC 20515

The Honorable Kevin McCarthy House
House Minority Leader
2468 Rayburn House Office Building
Washington, DC 20515

The Honorable Charles Schumer Senate
Senate Majority Leader
322 Hart Senate Office Building
Washington, DC 20510

The Honorable Mitch McConnell
Senate Minority Leader
317 Russell Senate Office Building
Washington, DC 20510

Dear President Biden, Speaker Pelosi, Senate Majority Leader Schumer, Leader McConnell, and Leader McCarthy:

On behalf of Research!America, thank you for your extraordinary leadership and for your respective roles in accelerating the pace of medical progress and access to its benefits. In that context, we urge you to reauthorize the Food and Drug Administration user fee programs before September 30, 2022.

Your individual and collaborative efforts have contributed to unprecedented strides in the treatment and cure of deadly and debilitating health threats. By ensuring timely passage of FDA user fee legislation in past Congresses, you have also played a profoundly important role in equipping the Food and Drug Administration (FDA) to modernize and increase the time- and cost-efficiency of regulatory decision-making.

In that context, we urge you to act swiftly to reauthorize FDA User Fee programs before they expire on September 30, 2022. Failure to reauthorize these programs by that date will compromise FDA's ability to sustain hard-won advances in regulatory rigor and efficiency that increase the societal returns of science. These societal returns compound over time. With each day that passes, more individuals lose hope, quality of life, or their very lives to health threats for which potential solutions have been developed. The faster we isolate and enable access to safe and effective medical advances, the greater the total number of people who benefit in profoundly important ways.

241 18th Street South
Suite 501
Arlington, VA 22202

P 703.739.2577

F 703.739.2372

E info@researchamerica.org

The user fee programs will expire in a matter of weeks absent congressional and presidential action. Please do not allow that possibility to turn into a reality.

Thank you again, President Biden, Speaker Pelosi, Leader Schumer, Leader McConnell, and Leader McCarthy, for your service to our nation, and please extend our thanks to your respective teams for their hard work and commitment.

Respectfully,

A handwritten signature in cursive script that reads "Mary Woolley". The signature is written in black ink and is positioned above the printed name and title.

Mary Woolley
President and CEO